EXCLUSIVE Investment Opportunity | LIFE raise open to all investors: Theralase® is raising up to $5.3M to complete bladder cancer study

Clinical stage pharmaceutical company Theralase Technologies Inc. (TSXV:TLT) announced a brokered financing with Research Capital Corporation to raise for up to C$5.3 million. [Open in your browser]( [Stockhouse.com](  [alt_text] Theralase® is raising up to $5.3M to complete bladder cancer study [alt_text] [alt_text]( [alt_text] Theralase Technologies - Focused on commercialization of next generation Photo Dynamic Compounds (“PDCs”) for the treatment Non-Muscle Invasive Bladder Cancer (“NMIBC”). [alt_text] RAISING $3.5 to $5.3 million CAD SECTOR Healthcare TERMS $0.22 CAD per Unit (1 full share + 1 full share warrant at $0.28 CAD for 5 years) --------------------------------------------------------------- INVESTMENT OPPORTUNITY - Multi-billion dollar opportunity as bladder cancer is the 10th most common cancer in the world (6th in men) - Best-in-class treatment for NMIBC (according to interim clinical data) - Investment opportunity open to all investors [VIEW DEAL]( Theralase® is raising up to $5.3M to complete bladder cancer study - Theralase Technologies is announcing a brokered financing to raise for up to C$5.3 million - Proceeds of the financing will be used to further a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study - Ruvidar™ is designed to destroy solid core tumours, such as bladder, brain, lung and breast, when absorbed by the cancer cell and then light or radiation activated - Bladder cancer is the 10th most common cancer worldwide - The clinical study is to help test those who are “BCG” unresponsive to bladder cancer treatment Coreena Robertson interviews Roger Dumoulin-White, President and CEO Clinical stage pharmaceutical company [Theralase Technologies Inc. (TSXV:TLT)]( announced a brokered financing with Research Capital Corporation to raise for up to C$5.3 million. The company plans to use the proceeds of the financing to further a [Phase II non-muscle invasive bladder cancer (NMIBC) clinical study]( which is currently underway. If the maximum of the amount of the financing of C$5.3 million is subscribed to, it will additionally fund a Good Laboratory Practices (“GLP”) toxicology study for the intravenous installation of Rutherrin® (Ruvidar™ + transferrin) intended for the treatment of Glio Blastoma Multiforme (“GBM”). [Ruvidar™]( is designed to destroy solid core tumours, such as: bladder, brain, lung and breast cancer, when absorbed by the cancer cell and then light or radiation activated. The clinical study has been designed to enroll 100 patients and to date has treated 63. CEO and President Roger Dumoulin-White states that, “The interim clinical data has been amazing, both from a safety and an efficacy point of view.” He went on to add, “It’s been stronger than two immunotherapy drugs brought to market recently by large pharmas.” Bladder cancer is the 10th most common cancer worldwide. More than half a million new cases of bladder cancer occur annually, according to the World Cancer Research Fund. “Half of Canadians will contract cancer during their lifetime. A quarter will die from it,” Dumoulin-White said. The current standard of care of NMIBC is intravesical Bacillus Calmette Guérin (“BCG”). Dumoulin-White said unfortunately BCG doesn’t work for everybody. “Patients fail BCG treatment, which is the standard of care. So you have these patients, which are BCG unresponsive and unfortunately they don’t have a lot of treatment options. This is why Theralase® is looking to bring our technology to market for these patients, who are suffering from this deadly disease,” Dumoulin-White said. Over the next six months the company is working on a pre-breakthrough designation approval for the FDA and will focus on enrolling and treating and additional 37 patients in the clinical study. The company has [28 issued patents and 17 patents pending for PDC]( and laser technology in the United States, Canada and internationally. Theralase® is dedicated to the research and development of light and/or [radiation activated Photo Dynamic Compounds (“PDCs”)]( for the safe and effective destruction of various cancers, bacteria and viruses. For more information on Theralase®, check out [www.theralase.com](. Join the discussion: Find out what everybody’s saying about this stock on the [Theralase® Bullboard]( and check out the rest of [Stockhouse’s stock forums and message boards](. This is sponsored content issued on behalf of Theralase®, please see the [full disclaimer here](. Disclaimer: Theralase® is currently conducting a Phase II NMIBC clinical study for regulatory approval in Canada and the United States. The Theralase® Anti-Cancer Therapy (“ACT”) is currently not Health Canada or FDA approved. [VIEW DEAL]( FULL DISCLOSURE: Stockhouse is not registered as a broker, dealer, exempt market dealer, or any other registrant in any securities regulatory jurisdiction and will not be performing any registerable activity as defined by the applicable regulatory bodies. This DEALROOM is for informational purposes only and does not constitute an offer to sell or a solicitation to buy the securities referred to herein. Offers to sell, or the solicitations of offers to buy, any security can only be made through official offering documents that contain important information about risks, fees, and expenses. In all cases, parties should conduct their own investigation and due diligence, not rely solely on the data provided herein and are encouraged to consult with a financial adviser, lawyer, accountant, and any other professional that can help to understand and assess the risks associated with any investment opportunity. --------------------------------------------------------------- [stockhouse]( Stockhouse Publishing Ltd. 1100 – 609 West Hastings Street | Vancouver | BC | V6B 4W4 | CA [Unsubscribe]( | [Manage Preferences]( [Facebook]( [Twitter]( [LinkedIn]( This email was sent to you by Stockhouse Publishing Ltd. because you consented to receive messages from us. You may manage your subscription preferences at any time. You may contact our email compliance officer at compliance@stockhouse.com